ES2236447T3 - Compuestos de sulfonilpiridazinona como agentes terapeuticos para dañom tisular por isquemia. - Google Patents

Compuestos de sulfonilpiridazinona como agentes terapeuticos para dañom tisular por isquemia.

Info

Publication number
ES2236447T3
ES2236447T3 ES02253605T ES02253605T ES2236447T3 ES 2236447 T3 ES2236447 T3 ES 2236447T3 ES 02253605 T ES02253605 T ES 02253605T ES 02253605 T ES02253605 T ES 02253605T ES 2236447 T3 ES2236447 T3 ES 2236447T3
Authority
ES
Spain
Prior art keywords
pyridazin
alkyl
compound
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02253605T
Other languages
English (en)
Spanish (es)
Inventor
Banavara L. Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2236447T3 publication Critical patent/ES2236447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES02253605T 2001-05-24 2002-05-22 Compuestos de sulfonilpiridazinona como agentes terapeuticos para dañom tisular por isquemia. Expired - Lifetime ES2236447T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29339301P 2001-05-24 2001-05-24
US293393 2001-05-24

Publications (1)

Publication Number Publication Date
ES2236447T3 true ES2236447T3 (es) 2005-07-16

Family

ID=23128899

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02253605T Expired - Lifetime ES2236447T3 (es) 2001-05-24 2002-05-22 Compuestos de sulfonilpiridazinona como agentes terapeuticos para dañom tisular por isquemia.

Country Status (15)

Country Link
US (1) US6872722B2 (https=)
EP (1) EP1260224B1 (https=)
JP (1) JP2002370984A (https=)
KR (1) KR20020090321A (https=)
CN (1) CN1390547A (https=)
AT (1) ATE289510T1 (https=)
AU (1) AU761191B2 (https=)
CA (1) CA2387007A1 (https=)
CZ (1) CZ20021782A3 (https=)
DE (1) DE60203026T2 (https=)
ES (1) ES2236447T3 (https=)
HU (1) HUP0201738A3 (https=)
PL (1) PL354128A1 (https=)
SK (1) SK7332002A3 (https=)
ZA (1) ZA200203985B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DK1961420T3 (da) * 2005-12-16 2012-08-27 Sanwa Kagaku Kenkyusho Co Middel til forebyggelse og behandling af akut nyresvigt
KR20080108465A (ko) * 2006-02-20 2008-12-15 가부시키가이샤산와카가쿠켄큐쇼 뇌졸중에 있어서의 뇌허혈 또는 뇌허혈 재관류 장해의 예방또는 치료제
WO2022197487A1 (en) 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH01258671A (ja) * 1987-12-01 1989-10-16 Morishita Pharmaceut Co Ltd ５−（１ｈ−イミダゾール−１−イル）−３（２ｈ）−ピリダジノン誘導体
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
WO1992017446A2 (en) * 1991-03-28 1992-10-15 Pfizer Inc. Pyridazinone acetic acids aldose reductase inhibitors
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
CN1142148C (zh) * 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
CA2442476A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors

Also Published As

Publication number Publication date
US6872722B2 (en) 2005-03-29
AU761191B2 (en) 2003-05-29
EP1260224B1 (en) 2005-02-23
JP2002370984A (ja) 2002-12-24
DE60203026D1 (de) 2005-03-31
CN1390547A (zh) 2003-01-15
CZ20021782A3 (cs) 2003-03-12
EP1260224A1 (en) 2002-11-27
HUP0201738A2 (hu) 2003-02-28
HUP0201738A3 (en) 2003-11-28
ATE289510T1 (de) 2005-03-15
US20030008871A1 (en) 2003-01-09
ZA200203985B (en) 2003-11-20
DE60203026T2 (de) 2006-05-04
PL354128A1 (en) 2002-12-02
KR20020090321A (ko) 2002-12-02
SK7332002A3 (en) 2003-05-02
AU4068502A (en) 2002-11-28
HU0201738D0 (https=) 2002-07-29
CA2387007A1 (en) 2002-11-24

Similar Documents

Publication Publication Date Title
US20240294526A1 (en) Fused tri-cyclic compound as a pde3/pde4 dual inhibitor
ES2563952T3 (es) Compuesto de 8-oxoadenina 9-sustituido
US8138172B2 (en) 8-oxoadenine derivatives acting as modulators of TLR7
ES2361595T3 (es) Compuestos orgánicos.
ES2627433T3 (es) Derivados de purina
CA2559552A1 (en) Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
BR112015017929B1 (pt) Dihidropirimidinonas bicíclicas substituídas, composição farmacêutica que os compreende e uso
US9006433B2 (en) Substituted pyrimidines
ES2236447T3 (es) Compuestos de sulfonilpiridazinona como agentes terapeuticos para dañom tisular por isquemia.
ES2240657T3 (es) Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
US20040110954A1 (en) Methods of synthesizing phenol-contining compounds
AU2002236131B2 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
ES2575688T3 (es) Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
AU2002236131A1 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
ES2246464T3 (es) Procedimiento e intermedios para agentes antidiabeticos de piridazinona.
ES2230576T3 (es) 4-amino-2-ureido-pirimidin-5-carboxamidas, procedimiento para su preparacion, medicamentos que contienen estos compuestos, y su uso.
US20240300968A1 (en) 6-substituted naphthalene-1,3-disulfonic acid derivatives as modulators of the extracellular nicotinamide phosphoribosyl transferase (enampt) for the treatment of e.g. diabetes
RS52571B (sr) Derivati imidazola sa afinitetom prema aktivnosti alfa 2 receptora
CN118852152A (zh) 哒嗪酮类化合物及其制备方法和用途